Patricia Remalante‐Rayco

Patricia Remalante‐Rayco

Auto-generated profile, based on publicly available information

Patricia Remalante‐Rayco

Institute of Medical Science, Temerty Faculty of Medicine University of Toronto Toronto Ontario Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2020 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
PRPatricia Pauline M. Remalante
Patricia Pauline M. Remalante
ESEvelyn O. Salido
Evelyn O. Salido
EPEster G. Penserga
Ester G. Penserga
DGDeonne Thaddeus V. Gauiran
Deonne Thaddeus V. Gauiran

10 May 2026 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
PRPatricia Remalante‐Rayco
Patricia Remalante‐Rayco
LPLaura Passalent
Laura Passalent
TCTina Chim
Tina Chim
HVHannah Vijayan
Hannah Vijayan
MAManal Alnasser
Manal Alnasser
DPDenis Poddubnyy
Denis Poddubnyy
Objective: The purpose of this study was to estimate the prevalence of difficult‐to‐manage (D2M) and treatment‐refractory (TR) axial spondyloarthritis (axSpA) and to identify factors associated with D2M and TR disease in a longitudinal cohort. Methods: We performed a cross‐sectional analysis on data from the Schroeder Arthritis Institute Spondylitis Program cohort. Assessment of SpondyloArthritis International Society (ASAS) definitions for D2M and TR disease were applied to patients with axSpA. Sociodemographic and disease‐related characteristics were compared between groups, and multivariable logistic regression was performed to estimate odds ratios (ORs) for factors associated with D2M. Results: Among 536 patients, 49 (9.1%) met the ASAS D2M definition and 12 (2.2%) were classified as having TR axSpA. Compared with patients with non‐D2M axSpA, those with D2M axSpA exhibited higher disease activity, worse function and spinal mobility, and a higher prevalence of comorbidities, degenerative spine disease, and fibromyalgia. patients with TR axSpA showed greater disease burden and more often were male, were HLA‐B27–positive, and had radiographic axSpA, but they were less affected by noninflammatory pain contributors. In multivariable analysis, higher spinal pain scores (OR 1.48 [95% confidence interval (CI) 1.29–1.70]) and fibromyalgia (OR 3.09 [95% CI 1.33–7.15]) were independently associated with D2M. Conclusion: Approximately 1 in 10 patients with axSpA in this cohort fulfilled the ASAS D2M definition, with a smaller proportion classified as having TR axSpA. D2M status was associated with higher spinal pain and fibromyalgia, whereas patients with TR axSpA had active disease with fewer noninflammatory pain contributors. These findings support the clinical relevance of the D2M construct and highlight the need for a tailored management approach in clinical practice. image

4 October 2023 in Rheumatology
Verified
Journal Article
Closed access
PDF file
PRPatricia Remalante-Rayco
Patricia Remalante-Rayco
AEAdrian I Espiritu
Adrian I Espiritu
YDYassir Daghistani
Yassir Daghistani
TCTina Chim
Tina Chim
EAEshetu Atenafu
Eshetu Atenafu
RIRobert Davies Inman
Robert Davies Inman
To investigate the incidence of demyelinating disease (DD) among spondyloarthritis (SpA) patients and identify risk factors that predict DD in this patient population. Axial SpA (axSpA) and psoriatic arthritis (PsA) patients were identified from a longitudinal cohort database. Each group was analysed according to the presence or absence of DD. Incidence rates (IR) of DD were obtained with competing risk analysis. Cox regression analysis with Fine and Grey’s method was used to evaluate predictors of DD development. Among 2260 patients with follow-up data, we identified 18 DD events corresponding to an average IR of 31 per 100 000 persons per year for SpA. The IR of DD at 20 years was higher in axSpA than in PsA (1.30% vs 0.13%, p= 0.01). The risk factors retained in the best predictive model for DD development included ever- (versus never-) smoking (HR 2.918, 95% CI 1.037–8.214, p= 0.0426), axSpA (versus PsA) (HR 8.790, 95% CI 1.242–62.182, p= 0.0294), and presence (versus absence) of IBD (HR 5.698, 95% CI 2.083–15.589, p= 0.0007). History of TNFi therapy was not a predictor of DD. The overall incidence of DD in this SpA cohort was low. Incident DD was higher in axSpA than in PsA. A diagnosis of axSpA, the presence of IBD, and ever-smoking predicted the development of DD. History of TNFi use was not found to be a predictor of DD in this cohort.

18 August 2025 in Rheumatology
Verified
Journal Article
Closed access
PRPatricia Remalante-Rayco
Patricia Remalante-Rayco
YDYassir Daghistani
Yassir Daghistani
TCTina Chim
Tina Chim
ZBZeynep Baskurt
Zeynep Baskurt
SKSareh Keshavarzi
Sareh Keshavarzi
NHNigil Haroon
Nigil Haroon
Objectives: To examine whether inflammatory bowel disease (IBD) influences disease activity and radiographic progression in patients with axial spondyloarthritis (axSpA). Methods: This was a longitudinal cohort study of axSpA patients from a tertiary referral centre. Active axSpA was assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI ≥4) in a dataset of 1268 patients. Radiographic progression, defined as a ≥ 2-unit increase in the modified Stoke Ankylosing Spondylitis Score (mSASSS) over 2 years, was evaluated in a subset of 471 patients with available longitudinal radiographic data. Generalized estimating equation models were used to assess associations between IBD and each outcome, adjusting for key confounders. Results: Among 1451 axSpA patients, 184 (13%) had IBD. Compared with axSpA-only patients, those with IBD had lower HLA-B27 positivity and higher rates of uveitis, peripheral arthritis and elevated C-reactive protein. However, IBD was not associated with an increased risk of active axSpA (OR 0.98, 95% CI 0.75–1.28) or radiographic progression (OR 1.45, 95% CI 0.78–2.73). Sensitivity analyses accounting for time-varying IBD status confirmed these findings. Conclusion: AxSpA-IBD patients exhibited distinct clinical features but did not have worse disease activity or greater radiographic progression than those with axSpA alone. These findings suggest that while IBD and axSpA share overlapping immunopathogenic mechanisms, IBD does not exacerbate axSpA severity. Further research is needed to explore the effects of IBD severity and duration on long-term axSpA outcomes to delineate the interaction between these two diseases.

2 November 2021 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
PRPatricia Pauline Remalante-Rayco
Patricia Pauline Remalante-Rayco
PDPatricio Iii Espinoza Dumlao
Patricio Iii Espinoza Dumlao
ASAngeline-Therese Santiago
Angeline-Therese Santiago
A 33-year-old man presented with a 2-year history of right knee swelling with fungating masses and white-yellow discharge. Severe pain, limited movement and signs of sepsis were absent. Debridement, partial synovectomy and arthrotomy were done for the multiple sinuses that developed over the knee. Synovial tissue analysis yielded a positive acid-fast bacillus smear and Mycobacterium tuberculosis PCR test, while aerobic culture studies grew Pseudomonas aeruginosa and Acinetobacter baumannii. Chronic granulomatous inflammation was seen on histopathology. Alongside antibiotic therapy, multiple debridements of the right knee were required to eradicate the infection and allow wound repair. A flap coverage with split-thickness skin graft was performed after the bacterial infection resolved, and the patient was discharged ambulatory with minimal pain. Such atypical presentations of monarthritis require immediate workup and a prompt referral to a multidisciplinary team to establish the diagnosis and initiate appropriate management before irreversible joint destruction and disability ensues.

4 June 2026 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
PRPatricia Remalante‐Rayco
Patricia Remalante‐Rayco
DPDenis Poddubnyy
Denis Poddubnyy